SCHEMBL617279

SCHEMBL617279

Cc1nc2ncccc2cc1C(=O)NC(C)c1ccc(-c2cccnc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUCNR1 Q9BXA5 4/20 0.44
OXGR1 Q96P68 1/20 0.44
USP2 O75604 1/20 0.43
PDE2A O00408 2/20 0.43
PHGDH O43175 1/20 0.43
CNR2 P34972 1/20 0.43
PPARG P37231 1/20 0.42
CLK1 P49759 4/20 0.42
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
MTOR P42345 1/20 0.41
PIK3CG P48736 1/20 0.41
PRKDC P78527 1/20 0.41
ATM Q13315 1/20 0.41
ATR Q13535 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
ROCK2 O75116 1/20 0.41
RPS6KA5 O75582 1/20 0.41
MAP4K4 O95819 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL619556 1.00 SUCNR1 (0.44) SUCNR1OXGR1USP2PDE2APHGDH
SCHEMBL617278 1.00 SUCNR1 (0.44) SUCNR1OXGR1USP2PDE2APHGDH
SCHEMBL618479 0.86 CLK1 (0.53) USP2PDE2APHGDHCNR2CLK1
SCHEMBL251862 0.84 PDE2A (0.50) PDE2A
SCHEMBL251861 0.84 PDE2A (0.50) PDE2A
SCHEMBL619018 0.84 PDE2A (0.50) PDE2A
SCHEMBL616898 0.82 PDE2A (0.49) SUCNR1PDE2AMAPK1
SCHEMBL616899 0.82 PDE2A (0.49) SUCNR1PDE2AMAPK1
SCHEMBL618473 0.81 KCNK3 (0.41) SUCNR1OXGR1PDE2ACNR2CLK1
SCHEMBL618475 0.81 KCNK3 (0.41) SUCNR1OXGR1PDE2ACNR2CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401275-B1 NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY RESPIRATORIUS AB (SE) 2013-07-24 EP claimed
US-8415333-B2 Bronchodilating diazaheteroaryls RESPIRATORIOUS AB (SE) 2013-04-09 US claimed
US-20120040942-A1 NOVEL BRONCHODILATING DIAZAHETEROARYLS RESPIRATORIUS AB (SE) 2012-02-16 US claimed
EP-2401275-B1 NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY RESPIRATORIUS AB (SE) 2013-07-24 EP disclosed
US-8415333-B2 Bronchodilating diazaheteroaryls RESPIRATORIOUS AB (SE) 2013-04-09 US disclosed
US-20120040942-A1 NOVEL BRONCHODILATING DIAZAHETEROARYLS RESPIRATORIUS AB (SE) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040942-A1 NOVEL BRONCHODILATING DIAZAHETEROARYLS CHRM3, ADRB1, ADRB3 SUCNR1 579/4885OXGR1 1240/4885USP2 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.